ALSO NOTED: FDA announces generic Risperdal, then retracts; Botox maker probed for off-label marketing

> The FDA announced that it had approved Ranbaxy's version of the Johnson & Johnson antipsychotic Risperdal--only the Indian firm hadn't applied. The agency quickly issued a retraction; Risperdal isn't scheduled to go off-patent till June. Report

> Botox maker Allergan may be in hot water for promoting the injection as a headache remedy, an off-label use; the Department of Justice is investigating. Report | Report

> Sanofi-Aventis got European approval to sell a 300 mg "loading dose" of its blood-thinner Plavix. Report

> A Nigerian court granted bail to a former Pfizer exec jailed in connection with a lawsuit over a meningitis drug trial in that country. Report

> Drug developers with questionable data beware. The FDA is taking no prisoners, and handing out no approvals, for developers suffering from data integrity issues. Report

> Cambridge, Massachusetts has been home to many of the world's most innovating drug developers--and now it's home to a start-up in the biotech fold that is pioneering a pricey new service to map the entire genetic code of individuals. Report

> When is a cancer therapy good enough? The Boston Globe examines answers to that question following the recent controversy over the FDA's decisions in the field. Report

> Leaders in the nanotech field have been beating a path to Congress, asking lawmakers to significantly boost federal support of research into molecular-level advances. Report

> Hormones produced by the heart could play a remarkable role in controlling and perhaps even curing cancer. Report

> Forget those studies of long-lived Italian shepherds and Greek fishermen. It's not fresh air or exercise or a simple whole-foods diet that causes certain people to live past 100, a new study shows. Instead, it's a set of genetic mutations thought to interfere with normal cell growth and thus slow aging. Report

And Finally... Several of the world's top biomedical research institutes--including a couple run by biopharma giants--have made this year's list of the best places for postdocs to work. Report

Suggested Articles

Pfizer’s Ibrance has met with success in breast cancer since breaking onto the scene in 2015. But its first foray into early breast cancer was a bust.

After years of having first-line liver cancer market to itself, Bayer’s Nexavar is getting major competition from Roche's Tecentriq.

Most of the recent enthusiasm around AbbVie’s new drugs has centered on Skyrizi and Rinvoq, but elagolix wants a piece of the spotlight, too.